| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed |
|---|---|---|---|---|---|---|
| **NUPLAZID® (pimavanserin)**[1] | Parkinson's Disease Psychosis | | | | | |
| **DAYBUE™ (trofinetide)**[2] | Rett Syndrome | | | | | |
| **Pimavanserin**[3] | Negative Symptoms of Schizophrenia | | | | | |
| **ACP-101**[4 5] | Hyperphagia in Prader-Willi Syndrome | | | | | |
| **ACP-204**[5] | Alzheimer's Disease Psychosis | | | | | |
| **ACP-2591**[5] | Rett Syndrome; Fragile X Syndrome | | | | | |
| **ASO Programs**[6] | SYNGAP1; Rett; Undisclosed | | | | | |
| **Undisclosed** | Neuropsychiatric Symptoms | | | | | |

[1] NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
[2] Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
[3] Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA.
[4] Acadia acquired Levo Therapeutics and its rights/licenses to ACP-101.
[5] ACP-101, ACP-204 and ACP-2591 are investigational agents, and the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.
[6] Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide.
Provided January 9, 2024 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.